Avicanna Inc. (USD) Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.

Avicanna Inc. (USD) Active

480 University Avenue, Toronto, ON, CA, M5G 1V2

Stock Price USD

Price Change

Last Dividend USD

D+

Latest Rating

AVCNF's stock peer is CAAOF (INDVR Brands Inc.)

AVCNF's stock peer is CNTMF (Fluent Corp.)

AVCNF's stock peer is CWBHF (Charlotte's Web Holdings, Inc.)

AVCNF's stock peer is EVRRF (Molecule Holdings Inc.)

AVCNF's stock peer is GBLP (Global Pharmatech, Inc.)

AVCNF's stock peer is ISCNF (Isracann Biosciences Inc.)

AVCNF's stock peer is IZOZF (Izotropic Corporation)

AVCNF's stock peer is MEDIF (MediPharm Labs Corp.)

AVCNF's stock peer is RAPH (Raphael Pharmaceutical Inc.)

AVCNF's stock peer is VYYRF (Voyageur Pharmaceuticals Ltd.)

Healthcare Drug Manufacturers - Specialty & Generic

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.

20%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.

2026-06-15 08:30:00

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 4,000,014 ‎‎units of the Company (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of $600,002.1 (“Offering”).

2026-06-12 17:30:00

Avicanna Reports Q1 2026 Financial Statements

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

2026-05-14 07:30:00

Avicanna Announces Results of Annual General and Special Meeting

TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management's nominees listed in the Company's management information circular dated April 2, 2026 (“Circular”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“Meeting”).

2026-05-08 07:30:00

Avicanna Announces Change in Board of Directors

TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026, has tendered her resignation as a member of the board of directors effective Friday May 1, 2026 ahead of the annual general and special meeting of shareholders.

2026-05-01 20:46:00

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update

Rescheduling aligns with Avicanna's established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives

2026-04-28 07:28:00

Annual General and Special Meeting of Shareholders to be held May 7, 2026

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general and special meeting of shareholders will be held virtually on Thursday, May 7, 2026 at 11:30 AM (Toronto Time).

2026-04-21 07:30:00

ThreeD Capital Inc. Issues Early Warning Report in Connection with Disposition of Securities of Avicanna Inc.

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions ending in recent weeks (the “Dispositions”), ThreeD disposed of ownership and control of an aggregate of 977,000 common shares (the “Subject Shares”) of Avicanna Inc. (the “Company” or “AVCN”). The Subject Shares represented approximately 0.8% of all issued and outstanding common shares of AVCN. As a result of the Dispositions, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) decreased by greater than 2%, on a partially diluted basis, from the last early warning report filed.

2026-04-07 19:49:00

Avicanna Announces Changes to its Board of Directors

TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces effective Thursday April 1, 2026 the resignation of John McVicar and pleased to announce the appointment of Mr. Ozgur Kilic to the Board of Directors of the Company.

2026-04-06 17:30:00

Avicanna Reports Full Year 2025 Audited Financial Statements

Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and international growth

2026-04-01 07:30:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions